Hims & Hers Health (NYSE: HIMS) reported another blowout quarter recently, but the stock didn't get the type of pop that ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

Hims & Hers is a rapidly emerging player in telehealth and wellness, catering to millennials and Gen Z. The company reported ...

TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Buy rating on the shares. The firm said HIMS has ample opportunities to grow weight loss as a ...

Hims' third-quarter results topped expectations, driven in part by revenue from its weight-loss drugs. The company said it ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the ...

Bearish flow noted in Hims and Hers Health with 30,788 puts trading, or 9x expected. Most active are Dec-24 21 puts and Dec-24 22 puts, with ...

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...